More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make existing immunotherapies more effective. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the new targets identified among the thousands of abstracts at AACR, as well as emerging pan-RAS inhibiting antibody-drug conjugates. The analysts also discuss Eli...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from BioCentury This Week
Ep. 369 - ASCO advances, China innovation & U.S. science under threat
Ep. 368 - ASCO Preview, China Policy, ADC Linkers
Ep. 367 - FDA, obesity targets and the rise of DACs
Ep. 366 - Europe's need for speed: Bio€quity takeaways
Get summaries like this every morning.
Free AI-powered recaps of BioCentury This Week and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.